Đánh giá Dược động học của Các Phân Bổ Thuốc Điều Trị Động Kinh Dạng Phóng Thích Từ Từ

Aldenkamp AP, Alpherts WCJ, Moreland MC, Ottevanger N, van Parys JAP. Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia 28: 507–514, 1987 Ballard BE. An over review of prolonged action drug dosage form. In Robinson (Ed.) Sustained and controlled release drug delivery systems, 1–64, Marcel Dekker, New York, 1978 Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effect of carbamazepine and carbamazepine-10, 11-epoxide: an update. Clinical Pharmacokinetics 11: 177–198, 1986 Bialer M, Friedman M, Dubrovsky J. Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs. Biopharmaceutics and Drug Disposition 5: 1–10, 1984a Bialer M, Friedman M, Dubrovsky J. Effect of sustained release on the pharmacokinetics of valproic acid in dog. International Journal of Pharmaceutics 20: 53–63, 1984b Bialer M, Friedman M, Dubrovsky J. Relation between absorption half life values of four novel sustained release dosage forms of valproic acid in dogs and humans. Biopharmaceutics and Drug Disposition 7: 495–500, 1986 Bialer M, Friedman M, Dubrovsky J, Raz I, Abramsky O. Pharmacokinetic evaluation of novel sustained release dosage forms of valproic acid in humans. Biopharmaceutics and Drug Disposition 6: 401–411, 1985 Bialer M, Friedman M, Rubinstein A, Dubrovsky J. Pharmacokinetic evaluation of a novel sustained release dosage form of valproic acid and intravenous preparation of valpromide in dogs. In Levy et al. (Eds) Metabolism of antiepileptic drugs, pp. 143–151, Raven Press, New York, 1984c Bialer M, Kaplan SA, Yacobi A. Animal models in the primary screening of controlled-release formulations. In Yacobi & Halperin-Walega (Eds) Oral sustained release formulations, pp. 183–193, Pergamon Press, New York, 1988 Eeg-Olofsson O, Nilsson HL, Tonnby B, Arvidisson J, Grahan PA, et al. Diurnal variation in carbamazepine and carbamazepine 10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations. Journal of Child Neurology 5: 159–165, 1990 Eichelbaum M, Tomson T, Tybring G, Bertilsson L. Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clinical Pharmacokinetics 10: 80–90, 1985 Faigle JW, Feldmann KF. Carbamazepine-biotransformation. In Levy et al. (Eds) Antiepileptic drugs, 3rd ed., pp. 491–504, Raven Press, New York, 1989 Jensen PK, Moller A, Gram L, Jensen NO, Dam M. Pharmacokinetic comparison of two carbamazepine slow-release formulations. Acta Neurologica Scandinavica 82: 135–137, 1990 Johannessen SI, Henriksen O. Comparison of the serum concentration profiles of Tegretol and two new slow-release preparations. In Wolf et al. (Eds) Advances in epileptology. XVIth Epilepsy International Symposium, pp. 421–424, Raven Press, New York, 1987 Kerr BM, Rettie AE, Eddy AC, Loiseau P, Guyot M, et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clinical Pharmacology and Therapeutics 46: 82–93, 1989 Kujoh T, Tanaka H, Hosokawa K, Matsumoto I. Pharmacokinetic analysis of a new slow-release preparation of valproic acid (KW 6066N). Japanese Journal of Psychiatry and Neurology 43: 511–512, 1989 Larkin TG, McLellan A, Munday A, Sutherland M, Butler et al. A double blind comparison of conventional and controlled-release carbamazepine in healthy subjects. British Journal of Clinical Pharmacology 27: 313–322, 1989 Levy RH. Valproate: modern perspectives. Epilepsia 25 (Suppl. 1): S1–S77, 1984 Levy RH, Shen DD. Valproate absorption, distribution and excretion. In Levy et al. (Eds) Antiepileptic drugs, 3rd ed., pp. 583–599, Raven Press, New York, 1989 Loo JCK, Riegelman S. New method for calculating intrinsic absorption rate of drugs. Journal of Pharmaceutical Sciences 57: 918–928, 1968 Loonen AJ, Toll PJ, Nijdam JR. A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients: preliminary pharmacokinetic results. Pharmaceutisch Weekblad 11: 23–26, 1989 May T, Rambeck B. Fluctuations of carbamazepine concentrations during the day for two slow-release preparations. Therapeutic Drug Monitoring 11: 21–24, 1989 McKee PJW, Blacklaw J, Butler E, Gillhan RA, Brodie MJ. Conventional versus controlled-release carbamazepine: double blind, double dummy, comparison. Acta Neurologica Scandinavica 82 (Suppl. 133): 51, 1990 McKee PJW, Bladelaw J, Butler E, Gillhan RA, Brodie MJ. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients. British Journal of Clinical Pharmacology 32: 99–104, 1991 Meijer JWA. Internationales Carbamazepin Slow-Release Symposium, Zuckschwerdt Verlag, Frankfurt, 1986 Meijer JWA, Binnie CB, Debetes RM, van Parys JAP, De Beer-Pawlikowski NKB. Possible hazard of valpromide-carbamazepine combination therapy in epilepsy. Lancet 1: 802, 1984 Morselli PL. Carbamazepine absorption, distribution and excretion. In Levy et al. (Eds) Antiepileptic drugs, 3rd ed., pp. 473–490, Raven Press, New York, 1989 Nau H. Pharmacokinetic aspects of drug teratogenesis: species differences and structure activity relationships of the anticonvulsant valproic acid. Acta Pharmacologica Jugoslavica 40: 291–300, 1990 Persson LI, Ben-Menachem E, Bengtsson E, Heinonen E. Differences in side effects between a conventional carbamazepine preparation and a slow-release preparation of carbamazepine. Epilepsy Research 6: 134–140, 1990 Porter RJ. Antiepileptic drugs: efficacy and inadequacy. In Meldrum & Porter (Eds) New anticonvulsant drugs, pp. 3–15, John Libbey, London, 1986 Porter RJ. General principles: how to use antiepileptic drugs. In Levy et al. (Eds) Antiepileptic drugs, 3rd ed., pp. 117–131, Raven Press, New York, 1989 Reunanen M, Heinonen E, Anttila M, Jarvensivu P, Lehto H, et al. Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation. Epilepsy Research 6: 126–133, 1990 Riad LE, Chan KKH, Wagner WE, Sawchuck RJ. Simultaneous first- and zero-order absorption of carbamazepine tablets in humans. Journal of Pharmaceutical Sciences 75: 897–900, 1986 Rubinstein A, Bialer M, Freidman M, Raz I, Abramsky O. A combined approach to control valproic acid release via novel drug delivery systems of valpromide: a kinetic and a pharmacokinetic study. Journal of Controlled Release 4: 33–35, 1986 Ryan SW, Forsythe I, Hartley R, Haworth M, Bowner CJ. Slow release carbamazepine in treatment of poorly controlled seizures. Archives of Disease in Childhood 65: 930–935, 1990 Shah AC. Design of oral sustained release drug delivery systems: in vitro and in vivo considerations. In Yacobi & Halperin-Walga (Eds) Oral sustained release formulation design and evaluation, 2nd ed., pp. 35–56, Pergamon Press, New York, 1988 Silber BM, Bialer M, Yacobi A. Pharmacokinetic/pharmacodynamic basis of controlled drug delivery. In Robinson & Lee (Eds) Controlled drug delivery, pp. 213–252, Marcel Dekker, New York, 1987 Sivenius J, Heinonen E, Lehto H, Jarvensivu P, Anttila M, et al. Reduction of dosing frequency of carbamazepine with a slowrelease preparation. Epilepsy Research 2: 32–36, 1988 Stefan H, Schafer H, Kuhnen C, Schneider S. Clinical monitoring during carbamazepine slow-release, once daily monotherapy. Epilepsia 29: 571–577, 1988 Takeda A, Hishida H, Amioka K, Sakamoto Y, Terao S, et al. Pharmacokinetic study of slow-release preparation of sodium valproate (KW-6066N): multiple dose administration test and the steady-state serum level profiles in epileptic patients. Japanese Journal of Psychiatry and Neurology 43: 515–516, 1989 Theeuwes F, Bayne W. Dosage form index: an objective criterion for evaluation of controlled-release drug delivery systems. Journal of Pharmaceutical Sciences 66: 1388–1392, 1977 Tomson T. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Archives of Neurology 4: 830–840, 1984 Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in absorptive phase after single doses of drug. Journal of Pharmaceutical Sciences 53: 1392–1403, 1964 Welling PG. Oral controlled drug administration: pharmacokinetic considerations. Drug Development and Industrial Pharmacy 9: 1185–1225, 1983 Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid — 1988. Clinical Pharmacokinetics 15: 367–389, 1988